Option Care Health (NASDAQ:OPCH) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Option Care Health (NASDAQ:OPCH) from a buy rating to a hold rating in a research note published on Sunday morning.

OPCH has been the topic of several other reports. Citigroup reaffirmed an “outperform” rating on shares of Option Care Health in a report on Friday, October 31st. Deutsche Bank Aktiengesellschaft lifted their price objective on Option Care Health from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Cowen initiated coverage on Option Care Health in a research report on Thursday, October 2nd. They set a “hold” rating for the company. Citizens Jmp reduced their price target on shares of Option Care Health from $38.00 to $36.00 and set a “market outperform” rating on the stock in a research report on Friday, October 31st. Finally, Morgan Stanley initiated coverage on shares of Option Care Health in a research note on Friday, October 17th. They issued an “overweight” rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.27.

Option Care Health Price Performance

OPCH stock opened at $32.93 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.05 and a current ratio of 1.56. The company’s fifty day moving average price is $28.98 and its 200-day moving average price is $29.33. Option Care Health has a one year low of $22.29 and a one year high of $35.53. The company has a market capitalization of $5.23 billion, a PE ratio of 26.14, a price-to-earnings-growth ratio of 2.26 and a beta of 0.80.

Insider Buying and Selling at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was purchased at an average price of $25.98 per share, for a total transaction of $987,240.00. Following the acquisition, the director owned 413,390 shares of the company’s stock, valued at $10,739,872.20. The trade was a 10.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPCH. Strs Ohio purchased a new stake in Option Care Health in the first quarter worth $636,000. Prospector Partners LLC boosted its position in Option Care Health by 22.9% in the 1st quarter. Prospector Partners LLC now owns 111,200 shares of the company’s stock valued at $3,886,000 after buying an additional 20,700 shares during the period. Advantage Alpha Capital Partners LP increased its position in shares of Option Care Health by 78.7% during the first quarter. Advantage Alpha Capital Partners LP now owns 214,619 shares of the company’s stock worth $7,501,000 after acquiring an additional 94,528 shares during the period. Andina Capital Management LLC purchased a new position in shares of Option Care Health during the first quarter worth approximately $513,000. Finally, Boston Partners raised its stake in shares of Option Care Health by 34.8% during the second quarter. Boston Partners now owns 952,299 shares of the company’s stock valued at $30,311,000 after acquiring an additional 245,990 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.